Keymed Biosciences (FRA:64Z) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:64Z Keymed Biosciences Inc FRA:64Z
44 GF Score
Price €8.45
GF Value €18.50
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Keymed Biosciences FFO?

FFO (Funds from operations) only applies to REITs.

FRA:64Z
44GF Score
Keymed Biosciences Inc FRA:64Z
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Keymed Biosciences (FRA:64Z) Overvalued in 2026?

Based on GuruFocus' analysis, Keymed Biosciences stock appears to be undervalued. The current stock price of €8.45 is trading 54.3% below its estimated GF Value™ of €18.50. GuruFocus considers Keymed Biosciences to be Possible Value Trap.

Key valuation signals for FRA:64Z:

  • FFO:
  • GF Value™: €18.50 vs. price of €8.45 (54.3% below fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the FRA:64Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Keymed Biosciences Business Description

Other Exchanges 02162:Hong Kong
Address No. 669 Fenghuang Road, Shuangliu District, Chengdu, Sichuan, CHN, 610219
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
44GF Score

Get the complete analysis for FRA:64Z

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.45
Price
€18.50
GF Value